Published in Ann Intern Med on July 17, 2001
Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ (2014) 2.80
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ (2004) 2.01
Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med (2007) 1.72
Diagnosis, investigation, and management of deep vein thrombosis. BMJ (2003) 1.31
How is deep vein thrombosis diagnosed and managed in UK and Australian emergency departments? Emerg Med J (2005) 1.06
Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med (2007) 1.04
Predictive Value of the Rapid Whole Blood Agglutination D-Dimer Assay (AGEN SimpliRED) in Community Outpatients with Suspected Deep Venous Thrombosis. Perm J (2006) 0.96
Role of fibrin D-dimer testing in emergency medicine. Emerg Med J (2003) 0.89
Usability Testing of a Complex Clinical Decision Support Tool in the Emergency Department: Lessons Learned. JMIR Hum Factors (2015) 0.85
African-American ethnicity is associated with higher plasma levels of D-dimer in adults with hypertension. J Thromb Haemost (2008) 0.79
Evaluation of the usefulness of a D dimer test in combination with clinical pretest probability score in the prediction and exclusion of Venous Thromboembolism by medical residents. Thromb J (2014) 0.77
Assessment of oxidative, inflammatory, and fibrinolytic biomarkers and DNA strand breakage in hypercholesterolemia. Inflammation (2013) 0.76
An older woman with pain and swelling of left leg. Malays Fam Physician (2010) 0.75
Perspective on the hospital incidence rate of deep venous coagulopathy: Clinical and biochemical diagnostic markers. Adv Biomed Res (2014) 0.75
Evaluation of the Simplify D-dimer assay as a screening test for the diagnosis of deep vein thrombosis in an emergency department. Emerg Med J (2004) 0.75
ACCESS: the acute cerebral CT evaluation stroke study. Emerg Med J (2004) 0.75
Clinical assessment and D-dimer testing in deep venous thrombosis. Ann Intern Med (2002) 0.75
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci U S A (1988) 3.25
Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation (1996) 3.23
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 2.74
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation (1996) 2.69
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med (1972) 2.60
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood (1991) 2.54
Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA (2001) 2.49
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
Establishing a therapeutic range for heparin therapy. Ann Intern Med (1993) 2.31
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Managing oral anticoagulant therapy. Chest (2001) 2.25
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med (1973) 2.17
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med (2000) 2.12
Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood (1999) 2.08
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation (2004) 2.05
Assessment of von Willebrand disease as a risk factor for primary postpartum haemorrhage. Haemophilia (2012) 2.05
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med (1981) 2.04
Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med (1998) 2.03
Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost (2014) 2.02
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Epidural analgesia for pain relief following hip or knee replacement. Cochrane Database Syst Rev (2003) 1.96
Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol (1966) 1.94
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest (1985) 1.92
Requirement of circadian genes for cocaine sensitization in Drosophila. Science (1999) 1.92
Ectopic G-protein expression in dopamine and serotonin neurons blocks cocaine sensitization in Drosophila melanogaster. Curr Biol (2000) 1.90
Does this patient have deep vein thrombosis? JAMA (1998) 1.90
A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation (1995) 1.90
Interactions of warfarin with drugs and food. Ann Intern Med (1994) 1.88
Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet (1970) 1.84
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol (2001) 1.76
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost (2014) 1.74
The antidepressant-sensitive dopamine transporter in Drosophila melanogaster: a primordial carrier for catecholamines. Mol Pharmacol (2001) 1.73
A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med (1999) 1.72
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2000) 1.71
A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med (2000) 1.70
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess (2012) 1.70
Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med (2001) 1.70
Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med (2001) 1.68
CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. Proc Natl Acad Sci U S A (1991) 1.68
Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost (2008) 1.67
Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA (1998) 1.67
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med (1986) 1.67
Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems. Br Med J (1968) 1.66
Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. N Engl J Med (1977) 1.66
Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med (1982) 1.64
Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med (2015) 1.62
The trace amine tyramine is essential for sensitization to cocaine in Drosophila. Curr Biol (1999) 1.60
Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke (2000) 1.59
A review of upper extremity deep vein thrombosis in pregnancy: unmasking the 'ART' behind the clot. J Thromb Haemost (2006) 1.59
Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. Can Med Assoc J (1976) 1.59